LabGenius speeds up AI-based drug discovery with Graphcore IPUs

LabGenius is engaged in AI-driven scientific research that could only have happened at this moment in time, and the cause couldn't be more important. Today, the company is focused on accelerating the discovery of advanced treatments for cancer and inflammatory diseases, but the principles can be applied far more widely. Using a combination of artificial intelligence, synthetic biology and laboratory automation, the London-based biotech company is developing next-generation antibody therapeutics. The technologies and techniques involved have only recently reached the level of maturity needed for this ambitious undertaking. So, when IPU systems halved the compute time needed to run crucial AI model training, LabGenius' researchers realised that they had found a new and important tool in the race to innovate.